B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.
Journal Article (Journal Article)
The B cell arm of the immune response becomes activated soon after HIV-1 transmission, yet the initial antibody response does not control HIV-1 replication, and it takes months for neutralizing antibodies to develop against the autologous virus. Antibodies that can be broadly protective are made only in a minority of subjects and take years to develop--too late to affect the course of disease. New studies of the earliest stages of HIV-1 infection, new techniques to probe the human B cell repertoire, the modest degree of efficacy in a vaccine trial and new studies of human monoclonal antibodies that represent the types of immune responses an HIV-1 vaccine should induce are collectively illuminating paths that a successful HIV-1 vaccine might take.
Full Text
Duke Authors
Cited Authors
- Haynes, BF; Moody, MA; Liao, H-X; Verkoczy, L; Tomaras, GD
Published Date
- February 2011
Published In
Volume / Issue
- 17 / 2
Start / End Page
- 108 - 116
PubMed ID
- 21112250
Pubmed Central ID
- PMC3053087
Electronic International Standard Serial Number (EISSN)
- 1471-499X
Digital Object Identifier (DOI)
- 10.1016/j.molmed.2010.10.008
Language
- eng
Conference Location
- England